With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

与 PD-1/PD-L1 阻断相比，CTLA-4 和 PD-1/PD-L1 双重阻断，并未显著改善复发/转移性宫颈癌（R/M CC）患者的临床结局。 华中科技大学 ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual ...

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, ...

Anti-PD-1 and anti-PD-L1 antibodies have resulted ... Besides the interaction between CTLA-4 and PD-1 with their respective ligands, other costimulatory and inhibitory interactions regulate ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline candidate, RP1 (vusolimogene oderparepvec), in combination with Bristol ...

In a commentary accompanying the study, Thomas Yau, MBBS, of the University of Hong Kong, and colleagues noted that anti-CTLA-4-based dual immune checkpoint inhibitor regimens have "revolutionized ...

Morgan Stanley downgraded Adagene (ADAG) to Equal Weight from Overweight with no price target While the firm believes anti-CTLA-4 approaches ...